ReviewDermatology and therapy2026
Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAndrogenetic alopecia (AGA) is a common condition in transgender and gender-diverse (TGD) individuals and may have an important psychosocial impact by exacerbating gender dysphoria and impairing quality of life. Hair loss patterns and treatment considerations in this population are influenced by genetic predisposition, cumulative androgen exposure, and the use of gender-affirming hormone therapy (GAHT). However, evidence-based guidance for the management of AGA in TGD individuals remains limited.
methodsA narrative review of the literature was conducted using PubMed, Embase, Cochrane, and ClinicalTrials.gov from database inception to 1 January 2026. Publications addressing the epidemiology, pathophysiology, clinical presentation, and management of AGA in TGD individuals were included. Evidence from cisgender populations was considered when TGD-specific data were lacking. Recommendations were formulated on the basis of available evidence and authors' clinical experience (dermatologists and endocrinologists).
resultsAGA in transgender men (TM) most frequently develops after initiation of masculinizing GAHT and follows a clinical course similar to cisgender men, whereas in transgender women (TW) it often reflects prior androgen exposure and may stabilize with feminizing GAHT. Oral minoxidil has emerged as a promising therapeutic option across TGD populations owing to its favorable efficacy and safety profile. Dosing should be individualized according to therapeutic goals, including scalp hair regrowth and, when desired, enhancement of beard or body hair. Higher doses may be carefully considered in select TM. The role of 5-alpha-reductase inhibitors appears more relevant in TM, while their benefit in TW with suppressed testosterone levels remains uncertain. Adjunctive therapies such as topical agents, mesotherapy with dutasteride, low-level laser therapy, platelet-rich plasma, and hair transplantation may complement medical treatment.
conclusionsAGA should be regarded as a clinically significant condition in TGD individuals rather than a purely cosmetic concern. Management requires an individualized, goal-oriented, and gender-affirming approach, with oral minoxidil representing a cornerstone of therapy. Given the limited high-quality evidence, further prospective studies are needed to define optimal treatment algorithms and long-term outcomes in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.